Clinical evaluation of protein C activity in sepsis-induced disseminated intravascular coagulation - PC-DIC study

ational Hospital Organization Kumamoto Medical Center0 个研究点目标入组 200 人开始时间: 2015年10月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•We exclude the following patients who may have conditions affecting prognosis other than infection, or affecting protein C activity. 1) Patients with hematopoietic malignancy such as leukemia, or solid cancer. 2) Patients having immunodeficiency disorder, such as myelodysplastic syndrome, myeloproliferative disorder, and acquired immunodeficiency syndrome. 3) Patients having severe liver cirrhosis (Child-Pugh B or C). 4) Patients having exogenous disease such as severe injury, severe burn,or heat stroke. Severe injury is defined as conditions having 3 points or more in at least one body part of AIS90 Update98. Severe burn is defined as conditions having 3 points or more in at least one body part of AIS90 Update98. Heat stroke is defined as grade III in Yasuoka classification. 5) Patients having protein C deficiency disease. 6) Patients or legal representative refuse written informed consent. 7) Patients receiving anti-DIC therapy at the time of entry, such as heparin (unfractionated heparin, low molecular weight heparin), heparinoid, antithrombin, recombinant human thrombomodulin, serine protease inhibitor (gabexate mesilate, nafamostat mesilete).

发起方

ational Hospital Organization Kumamoto Medical Center